Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

D. Van Der Heijde, A. Deodhar, O. FitzGerald

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)'. Together they form a unique fingerprint.

Medicine & Life Sciences